Search clinical trials for: Tenofovir Alafenamide

Total 1149 results

Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (DETOX)

HIV Infections

Spain
Gilead Sciences

Completed

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Chronic Hepatitis B

New Zealand
Professor Francois Venter
University of Cape Town

Completed

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants (EpiTAF)

Tuberculosis | HIV-1-infection

South Africa
Sunshine Lake Pharma Co., Ltd.

Completed

GLS4/RTV and TAF Drug-drug Interaction

Chronic Hepatitis B

China
University of California, Los Angeles
Gilead Sciences

Completed

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) (UCLACAREMITO)

HIV/AIDS | Mitochondrial Alteration | Antiviral Toxicity | Antiviral Drug Adverse Reaction

United States
Gilead Sciences

Completed

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) (BIC-STaR)

HIV-1-infection

Israel
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de Bellvitge

Completed

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

HIV-1-infection

Spain
Fenway Community Health

Completed

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

HIV Prevention

United States
Gilead Sciences
F-star Therapeutics, Inc.

Terminated

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Chronic Hepatitis B

Korea, Republic of, Hong Kong
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Spain, United States, Italy, Germany, United Kingdom, France, Australia, Puerto Rico, Canada, Belgium, Dominican Republic
Rhonda Brand
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs (APTAMER)

HIV | Medication Adherence

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

France, Spain, Germany, United Kingdom, United States, Puerto Rico, Belgium, Canada, Italy, Dominican Republic
Gilead Sciences

Completed

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

HIV-1-infection

United States, Puerto Rico, France, Germany, Austria, Canada
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Johns Hopkins University
Gilead Sciences

Completed

Analysis of Crushed and Whole Tablet Genvoya

Healthy Volunteers

United States
Fudan University

Active, not recruiting

Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant

HBV | POST LIVER TRANSPLANT

China
Philadelphia Fight
Gilead Sciences

Completed

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Hiv

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Chronic Hepatitis B

United States, Hong Kong, Korea, Republic of, Taiwan, United Kingdom, Canada, New Zealand, Italy
Yale University
Gilead Sciences

Withdrawn

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

Tuberculosis | Hiv

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (BRAAVE 2020)

HIV-1 Infection

United States
Emory University
Centers for Disease Control and Prevention

Completed

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

HIV/AIDS

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-56136379 in Healthy Participants

Healthy
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain
National Cheng-Kung University Hospital

Unknown

The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients. (HBV)

HBV

Taiwan
Young-Suk Lim
Samsung Medical Center; Seoul National University Hospital; Korea University... and other collaborators

Completed

Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.

Chronic Hepatitis b

Korea, Republic of
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
Midland Research Group, Inc.
Gilead Sciences

Completed

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Human Immunodeficiency Virus

United States
Assembly Biosciences

Completed

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection

Chronic Hepatitis B

New Zealand, United States, Canada
University of Colorado, Denver

Completed

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

Hepatitis C | HIV Coinfection

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Pharmacokinetics and Relative Bioavailability Study

Urinary Bladder, Overactive

Singapore
University of Colorado, Denver

Completed

The Cellular Pharmacology of F-TAF in Dried Blood Spots (TAF-DBS)

Healthy Volunteers

United States
National Taiwan University Hospital
Mackay Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital and other collaborators

Unknown

Same-day Antiretroviral Therapy With BIC/F/TAF

HIV Infections

Taiwan
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
New Discovery LLC

Unknown

Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

Hepatitis B, Chronic | Pregnancy Related

China
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection

Chronic Hepatitis B | Mother-to-child Block | Antiviral Treatment

China
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Hepatitis B Virus

United States, Germany, New Zealand
National Taiwan University Hospital

Unknown

Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus

Hepatitis B Virus Infection

Taiwan
Janssen-Cilag S.p.A.

Completed

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate (DIAMANTE)

Human Immunodeficiency Virus (HIV)

Italy
Gilead Sciences

Completed

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

HIV-1 Infection

Spain, United States, France, Italy, Germany, Canada, United Kingdom, Belgium, Puerto Rico, Australia
Thomas Jefferson University
University of Illinois at Chicago; University of California, San Francisco; Nova... and other collaborators

Completed

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

HIV/AIDS

United States
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme LLC

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression (GENIS)

HIV Infections | Severe Immunosuppression

Spain
Hospital Italiano de Buenos Aires
Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious...

Unknown

TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

COVID-19 | Healthcare Workers | SARS-CoV 2

Argentina
Gilead Sciences

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

HIV-1 Infection

Spain, France, United States, Germany, Italy
F-star Therapeutics, Inc.
PRA Health Sciences

Terminated

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Hepatitis B | Hepatitis B, Chronic | HBV

Hong Kong
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
Thomas Jefferson University
Gilead Sciences

Active, not recruiting

Entecavir to TAF Switch

Hepatitis B

United States
ViiV Healthcare

Completed

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

HIV Infections

United States
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
University Hospital Inselspital, Berne

Completed

TAF for HIV-HBV With Renal Dysfunction

HIV and Hepatitis B Coinfection

Switzerland
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium

3

Subscribe